These adaptions pose new challenges in people with CF (pwCF) in the post-CFTR modulator era, where patients are living longer, warranting the importance of understanding the longitudinal adaptations of pathogens post- highly effective CFTR modulator therapy (HEMT) [4,7,8,9]. The gene discussed is CFTR; the disease is cystic fibrosis.